GCM
MDGL icon

Graham Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Graham Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,062
Closed -$618K – 1380
2025
Q4 		$618K Buy
+1,062
New +$542K 0.01% 549
2025
Q3 		– Sell
-4,518
Closed -$1.37M – 1485
2025
Q2 		$1.37M Buy
4,518
+3,450
+323% +$1.03M 0.02% 482
2025
Q1 		$354K Buy
1,068
+409
+62% +$134K 0.01% 931
2024
Q4 		$203K Buy
+659
New +$185K ﹤0.01% 1074

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Graham Capital Management's MDGL Position: Q1 2026 in Review

Graham Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 1,062 shares — an estimated $618K sold.

Graham Capital Management first reported a position in MDGL in Q4 2024 and held it in 4 quarters. The position peaked at $1.37M in Q2 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Graham Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 1,062 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $618K.
  • Graham Capital Management first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Graham Capital Management's Madrigal Pharmaceuticals position peaked at $1.37M in Q2 2025.
  • 380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.